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ABSTRACT
Objectives: Using patient and expert provider input, we
previously developed a 15-item index of the most important
symptoms and concerns of people being treated for
advanced kidney cancer, the Functional Assessment of
Cancer Therapy—Kidney Symptom Index (FKSI). These 15
concerns are a mixture of disease-related symptoms
and treatment-related side effects. As a result, it may be
difﬁcult to assign an informative label to the score
deﬁned as the summation of these 15 most important
concerns. Because one of the primary goals of treating
advanced kidney cancer is the relief of disease-related
symptoms, we set out to differentiate from the list of 15
symptoms those that are predominantly attributable to
kidney cancer itself rather than its treatment, and to evalu-
ate this abbreviated FKSI—Disease-Related Symptoms
(FKSI-DRS).
Methods: Survey results from 18 experienced clinical experts
were summarized to separate DRS from other concerns more
arguably attributable to treatment side effects. This nine-item
FKSI-DRS was then validated on a sample of 141 people with
kidney cancer.
Results: The FKSI-DRS is reliable (internal consistency
range = 0.75–0.78; test–retest reliability intraclass correla-
tion = 0.85), and valid, separating groups by performance
status and the patient’s own global rating of change. The
likely minimally important difference in the FKSI-DRS is in
the range of 2–3 points.
Conclusions: The FKSI-DRS is a reliable, valid, and respon-
sive brief index of the most important symptoms associated
with advanced kidney cancer.
Keywords: disease-related, kidney cancer, renal cell cancer,
signs and symptoms.
Introduction
Patients with many types of advanced cancer, including
kidney cancer, face a reduced life expectancy and no
cure for their disease, making relief of physical symp-
toms and maintenance of function the primary objec-
tives of medical intervention [1–3]. This highlights the
need for a symptom index that can provide a clinically
appropriate and precise evaluation of symptomatology
and increased sensitivity to the impact of drug therapy.
The availability of such an instrument would allow
for the assessment of symptom beneﬁt, a potentially
important end point in clinical trial evaluations. Such
indexes may also be valuable when monitoring treat-
ment adherence, an increasingly important issue with
the expansion of oncology into oral chemotherapy.
Disease-speciﬁc symptom assessment has potential
to play a key role in evaluating patient-related end
points in clinical trials. The use of global quality of life
scores may obscure important and signiﬁcant changes
in disease-related symptoms when those symptoms are
embedded in a larger instrument [4], which under-
scores the importance of targeting assessment toward
prespeciﬁed, priority disease-related symptoms. Fur-
thermore, a scale comprised of symptoms that clini-
cians have determined to be disease-related could
function in support of a new drug approval for indi-
cation or label claim regarding beneﬁt to disease-
related symptoms.
We previously used patient and physician input to
develop and validate a 15-item scale to assess the most
important targeted symptoms and concerns related to
evaluating treatment effectiveness in advanced kid-
ney cancer, the Functional Assessment of Cancer
Therapy—Kidney Symptom Index-15 (FKSI-15) [5].
The FKSI-15 demonstrated good internal consistency,
convergent validity, successful differentiation of
patients known to differ in clinical status, and
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responsiveness to change in clinical status over time.
We also computed a minimally important difference
(MID) range of 3–5 points for the FKSI-15.
In regulatory review of the FKSI-15 and similar
scales, concern is often raised about the ﬁdelity of the
questions asked with regard to the label claim being
sought. For example, if one seeks to evaluate symp-
toms of disease that are important to patients, one
must ensure that those symptoms being measured are
not merely important, but also likely to be caused by
the disease process being treated. We therefore initi-
ated a project to differentiate disease-related from
treatment-related symptoms in this scale using in-
put primarily from clinical experts and secondarily
from kidney cancer patients, which resulted in the
FKSI—Disease-Related Symptoms (FKSI-DRS). The
objective was therefore to derive a brief index of
disease-related symptoms from the longer list of
symptoms known to be important to patients.
Because the FKSI-DRS is comprised of a subset of
items from the FKSI-15, we used patient data
from the FKSI-15 validation study to validate the
FKSI-DRS.
Methods
Participants
Physician sample: FKSI-DRS development and valida-
tion. Experts who treat kidney cancer were selected as
the appropriate group to help differentiate disease-
related symptoms and concerns from treatment-related
or other concerns. Although patients unquestionably
are expert at identifying what is most important or
valued to them, they are not objective evaluators of the
extent to which a symptom or problem is disease-
versus treatment-related. It is common (and arguably
an adaptive coping mechanism) for patients to inter-
pret their disease symptoms as caused by treatment or
other nonthreatening factors. Thus, asking experi-
enced physicians who are more objective about the
attribution of cause to a given priority symptom seems
necessary. After receiving approval from the institu-
tional review board, we identiﬁed 37 eligible experts
who were in national clinical cooperative groups, rec-
ognized key opinion leaders (based on publications
and presentations over the past 3 years), and medical
advisors to the Kidney Cancer Association (KCA);
email addresses were located for 35 of these experts. A
second reminder e-mail resulted in overall participa-
tion within a 10-day follow-up period of 18 physicians
(51.4%). We also distributed the survey to a group of
13 physician experts in kidney cancer who were par-
ticipating in an industry-sponsored kidney cancer
investigator meeting, for a total of 31 experts.
Sociodemographic information was collected on the
sample of 18 physicians but not on the remaining 13
(see Table 1). Of the 18 experts, the mean age was 47.7
(SD = 9.4) years and 89% were male. The mean
number of years in practice was 16.1 (SD = 7.8) and
ranged from 4 to 29 years. Physicians indicated their
medical specialty as either medical oncology (n = 15,
83%) or surgical urologic oncology (n = 3, 17%).
Over a third of the physicians (n = 6, 33%) reported
experience treating over 1000 patients with kidney
cancer, with over half of the sample of 18 (n = 11)
experienced at treating 200–999 patients.
Patient sample: FKSI-DRS validation. Patient data
from the FKSI-15 validation study was used for analy-
ses of the FKSI-DRS. Patients were constituents of a
national patient support and advocacy organization,
the KCA, who responded to information about the
study provided at a national conference, by postal
mailing, electronic mailing, or the KCA monthly elec-
tronic newsletter. Of 318 patients inquiring about the
study, 157 patients were eligible and were mailed a
consent form to be signed and returned along with
study materials. Interviews were scheduled with 143
Table 1 Description of patient and physician samples
Frequency Percent
Partial physician sample (n = 18)
Age (years)
Mean (SD) 47.67 (9.4)
Range 34–62
Sex
Male 16 88.9
Female 2 11.1
Number of patients treated
<200 1 5.6
200–499 4 22.2
500–999 7 38.9
1000+ 6 33.35
Patient sample (n = 141)
Age (years)
Mean (SD) 59.57 (9.8)
Range 37–82
Sex
Male 95 67.4
Female 46 32.6
Race/ethnicity (includes reports
of multiple ethnicities)
White 139
African American 1
Asian 0
American Indian/Alaskan native 2
Patient-rated ECOG performance status
Normal activity, without symptoms 65 46.4
Some symptoms, no bed rest 50 35.7
Some amount of bed rest 25 17.9
Prior chemotherapy
No 91 64.5
Yes 50 35.5
Prior radiation therapy
No 96 68.1
Yes 45 31.9
Currently receiving therapy
No 93 66.0
Yes 48 34.0
ECOG, Eastern Cooperative Oncology Group.
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patients; 14 were not enrolled because of: illness or
death (n = 2), declined participation (n = 6), failure to
return consent forms (n = 4), or invalid consent forms
(n = 2). One hundred forty-one patients with kidney
cancer ultimately participated in the validation phase
of this study (one patient who had consented died, one
could not be reached). There was good compliance
with the study assessments: 100% at time 1, 96% at
time 2 and 93% at time 3. Twelve patients went off-
study because of: death (n = 4), inability to contact
(n = 6), illness (n = 1), and administrative error (n = 1).
Complete data from all three assessments were avail-
able from 126 patients (89% of sample). A conve-
nience sample of 15 of these patients also participated
in a semistructured interview to obtain additional
patient input about priority kidney cancer symptoms.
The sociodemographic characteristics of the
patients are also summarized in Table 1. Participants
had a mean age of 60 (SD = 9.8) years, were mostly
male (67%) and predominately White (99%). Eighty-
two percent had an Eastern Cooperative Oncology
Group Performance Status Rating (ECOG PSR) of 0–1
at baseline, with a majority reporting a history of
treatment with chemotherapy (65%) or radiation
therapy (68%) and most currently receiving treatment
(66%).
Measures
FKSI-DRS development. We constructed a survey to
enable expert physicians to indicate on a per-item basis
whether each of the FKSI-15 items was exclusively
disease-related, predominantly disease-related, too
close to determine, predominantly treatment-related,
exclusively treatment-related, or neither disease- nor
treatment-related (see Table 2). Respondents were
asked to indicate one of the six possible response
options for each symptom/concern. In addition, the
ﬁrst 18 respondents were asked to provide descriptive
information including age, sex, medical specialty, years
in practice, and estimated total number of kidney
cancer patients treated. We used a predeﬁned scoring
system to tabulate results. Ratings of “exclusively
disease-related” or “exclusively treatment-related”
were given more weight (2 points) than those rated
“predominantly disease-related” or “predominantly
treatment-related” (1 point). Ratings of “too close to
determine” were assigned a score of “0.”
FKSI-DRS validation. Patients participating in the
validation of the FKSI-15 (and FKSI-DRS) completed
the Functional Assessment of Cancer Ther-
apy—General (FACT-G) [6], the ECOG PSR [7], and
the Global Rating of Change Scale (GRCS; adapted
from Jaeschke et al. [8]).
The FACT-G is a multidimensional health-related
quality of life (HRQL) instrument with established
reliability, validity and responsiveness to change [6].
The FACT-G contains 27 items divided among four
general subscales: Physical Well-Being (PWB), Social/
family Well-Being (SWB), Emotional Well-Being
(EWB), and Functional Well-Being (FWB) using a
ﬁve-point Likert-type scale ranging from 0 (“not at
all”) to 4 (“very much”). Scores are obtained for
each of the speciﬁc domains as well as a total HRQL
score.
The ECOG PSR [7] is a single-item rating of the
degree to which patients are able to participate in
typical activities without the need for rest. The PSR
ranges from 0 (“normal activity without symptoms”)
to 4 (“unable to get out of bed”). In this study, the PSR
was obtained from patients themselves and served as a
Table 2 Frequency of physician responses to FKSI items: disease- versus treatment-related
Exclusively
disease-related
Predominantly
disease-related
Too close to
determine
Predominantly
treatment-related
Exclusively
treatment-related Neither
I have a lack of energy 1 8 18 3 0 1
I am bothered by side effects
of treatment
0 0 4 15 12 0
I have pain 12 18 0 0 0 1
I am losing weight 2 15 12 0 0 1
I have bone pain 17 11 1 0 0 1
I feel fatigued 1 8 18 2 0 0
I am able to enjoy life 0 2 13 3 0 11
I have been short of breath 4 17 6 0 0 1
I worry that my condition will
get worse
15 10 4 0 0 1
I have a good appetite 0 3 11 3 0 12
I have been coughing 9 17 2 0 0 1
I am bothered by fevers 4 11 14 0 0 1
I am able to work (include
work at home)
0 1 15 2 1 10
I have had blood in my urine 17 10 1 0 0 2
I am sleeping well 0 2 14 3 0 11
FKSI, Functional Assessment of Cancer Therapy—Kidney Symptom Index.
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means of classifying patients for known-group
comparisons.
The GRCS [8] is a series of questions that ask
patients to rate the change in their health status over a
speciﬁed period of time. Questions about perceptions
of change in health status are speciﬁc to the domains of
interest (e.g., PWB, FWB). For each domain, patients
specify whether they are worse, about the same, or
better. If worse or better, patients then quantify the
magnitude of the recognized change using a rating
scale ranging from +7 (very great deal better) to -7
(very great deal worse).
Procedure
FKSI-DRS development. The surveys were distributed
to the expert clinicians via email (n = 18) and paper-
and-pencil (n = 13). Data were analyzed using two
methods. We ﬁrst examined the distribution of physi-
cians who endorsed each response category for each of
the FKSI-15 items. We then examined the means and
95% conﬁdence intervals (CIs) for each of the 15 FKSI
items.
A convenience sample of 15 patients from the
FKSI-15 validation sample was interviewed and
queried about the initial list of 18 potential FKSI-
DRS items, and their responses were qualitatively
summarized.
FKSI-DRS validation. The validation study used a
pre-post design to assess a patient’s experience of
symptoms and concerns associated with advanced
kidney cancer. Patients were assessed at three time
points: enrollment (baseline, or time 1), 3–7 days post
baseline (time 2), and 2–3 months post baseline (time
3). The FKSI-DRS is a subsample of items from the
FKSI-15. Data on the items comprising the FKSI-DRS
were extracted from the FKSI-15 validation data set
and analyzed to evaluate the validity of the FKSI-DRS.
Upon receipt of the signed consent form by the
research assistant, the patient completed the time 1
questionnaire battery via computer-assisted telephone
interview (CATI). A small number of patients attend-
ing the national conference were enrolled and com-
pleted the ﬁrst assessment in-person at the conference.
Although these two modes of administration might
produce different responses, available evidence sug-
gests essential comparability of in-person versus tele-
phone interview [9]. Three to 7 days after the baseline
assessment, all patients completed only the FKSI-15 by
CATI (time 2). To examine the FKSI-15’s responsive-
ness to change over time, patients completed the same
battery of questionnaires 2–3 months after the baseline
administration (time 3) by CATI.
Analysis plan. The FKSI-DRS was analyzed for inter-
nal consistency, test–retest reliability, convergent and
discriminant validity, and responsiveness to change in
clinical status. In addition, we estimated MIDs, which
have been deﬁned as the smallest score difference on a
HRQL questionnaire that is clinically signiﬁcant and
therefore likely to be meaningful to both patients and
clinicians [8,10,11].
Internal consistency analyses were performed at
each assessment for the FKSI-DRS using Cronbach’s
alpha coefﬁcients. Test–retest reliability was evaluated
by calculating an intraclass correlation (ICC) for the
FKSI-DRS at baseline and time 2 (3–7 days post base-
line). Cross-sectional analyses were conducted to
determine the ability of the FKSI-DRS to differentiate
deﬁnable (“known”) groups according to ECOG PSR.
Analysis of variance (ANOVA) techniques were used
to compare mean FKSI-DRS scores between ECOG
PSR categories. Effect sizes were calculated for group
comparisons to provide an indication of the clinical
signiﬁcance of group differences. The associations
between FKSI-DRS, FACT-G and subscale scores were
evaluated using correlational techniques. To examine
responsiveness to change, longitudinal data were used
to calculate FKSI-DRS change scores (baseline to time
3) for each patient. Patients were categorized as
“worse,” “same,” or “better” according to the global
rating of change scale. ANOVA techniques were used
to compare mean change scores on the FKSI-DRS
between categories of change in the anchor variable
(GRCS). As previously described [5], both
distribution- and anchor-based methods were used to
identify MIDs for the FKSI-DRS.
Results
FKSI-DRS Development
Physician ratings of the extent to which 15 FKSI items
were believed to be treatment- or disease-related were
examined for missing data. Less than 1% of the total
expected physician responses to the survey were
missing. Any responses of “neither” (54 of 465, 11.6%
of total) were excluded from the analyses. Table 2 and
Figure 1 summarize the physician ratings of the degree
to which items are disease- versus treatment-related.
Using the ﬁrst method of analyses, we identiﬁed
seven items that were categorized as either exclusively
disease-related (i.e., +2) or predominantly disease-
related (i.e., +1) by more than 50% of all respondents
(i.e., at least 16 of 31). These items assessed pain,
weight loss, bone pain, dyspnea (“shortness of
breath”), worry, cough, and hematuria (“blood in
urine”). Seven other items, although not clearly rated
by the majority as disease-related, were quite fre-
quently rated as “too close to determine.” This list
included lack of energy, fatigue, ability to enjoy life,
appetite, bothered by fevers, ability to work, and sleep.
Only the item “I am bothered by side effects of
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treatment” was clearly rated as predominantly
treatment-related.
Using the second method of analyses, we identiﬁed
nine items whose 95% CI did not fall below zero
(i.e., representative of the “too close to determine”
category). These items included all seven items iden-
tiﬁed as more disease-related by the ﬁrst method of
analyses, plus fever and fatigue. “Lack of energy”
came close to signiﬁcance, with the 95% CI touching
zero. This process produced a candidate set of 10
questions from the FKSI for consideration as likely
candidates for designation as FKSI-DRS: lack of
energy (borderline), pain, weight loss, bone pain,
fatigue, shortness of breath, worry that condition will
get worse, coughing, bothered by fevers, and blood in
urine. Of this list of 10 items, nine are physical symp-
toms. One is psychological (“I worry that my condi-
tion will get worse”), and not likely to be caused
directly by disease activity in any physical sense. On
the basis that it was highly unlikely that worry as a
symptom could be directly attributed as a symptom
of kidney cancer, it was deleted from further consid-
eration in the FKSI-DRS, resulting in a nine-item
scale (see Appendix I).
Because the reduction of the FKSI-15 to the nine-
item FKSI-DRS was based primarily on expert clinical
input, we obtained additional patient input during the
course of the FKSI-15 validation study. Speciﬁcally, we
interviewed 15 people with advanced kidney cancer
and asked them to respond to eight items that were
rated most associated with disease rather than treat-
ment, based on interim results of the expert survey
study (n = 18): pain, weight loss, bone pain, shortness
of breath, worry that condition will get worse, cough-
ing, bothered by fevers, and blood in the urine.
Patients were asked ﬁve questions: 1) whether the list
of eight expert-derived symptoms represented the most
important set of symptoms relative to their condition;
2) the relative importance of fatigue, sleep, and appe-
tite (which were missing from the short list); 3)
whether they had experienced signiﬁcant fatigue since
their diagnosis, and if so, whether they thought their
fatigue was more physical or mental, and what per-
centages they would assign to these attributions; 4)
whether they thought “fatigue” was different from
“lack of energy”; and 5) whether there were any other
symptoms they felt were associated with their condi-
tion that we should be asking about.
In response to the ﬁrst question, a majority of the 15
patients (n = 10, 67%) endorsed the list of items as the
most important symptoms relative to advanced kidney
cancer. Patients volunteered symptoms that were not
on the list, including fatigue/lack of energy (n = 3),
reaction of loved ones/concern about family relation-
ships (n = 3), and depression/worry (n = 1). Responses
to the second question revealed clear endorsement of
fatigue (n = 11) from patients and mixed endorsement
of appetite (n = 7) and sleep (n = 6) as problems asso-
ciated with advanced kidney cancer. Consistent with
the prior question, a majority of patients (n = 11,
73%) reported experiencing signiﬁcant fatigue since
their diagnosis, and most (n = 7, 64%) thought of their
fatigue as a physical manifestation as opposed to
mental (n = 1, 9% mental; n = 3, 27% both). Patients’
estimates of the extent to which they thought of their
fatigue as physical averaged 72% (range 40–99). Two-
thirds reported that fatigue was different than lack of
energy, but patients were unable to offer any consistent
distinction between the two concepts. When asked to
volunteer symptoms that were not on the list, patients
failed to generate any new candidate disease-related
symptoms.
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Figure 1 Expert ratings of disease- versus treatment-related attribution by symptom:Means and 95% conﬁdence intervals per FKSI Item. Items rated by
experts as “exclusively disease-related” received a score if (+2);“exclusively treatment-related” (-2);“predominantly disease-related” (+1),“predominantly
treatment-related” (-1), and ratings of “too close to determine” were assigned a score of 0. FKSI, Functional Assessment of Cancer Therapy—Kidney
Symptom Index.
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Validation of FKSI-DRS
The mean of the FKSI-DRS scores was similar at all
three time points: 29.1 (SD = 5.4) at time 1, 29.5
(SD = 4.7) at time 2, and 29.2 (SD = 5.3) at time 3.
Reliability
The FKSI-DRS showed high internal consistency at the
baseline assessment (Cronbach’s alpha [a] = 0.78),
time 2 assessment (0.75), and time 3 assessment (0.78).
Cronbach’s alpha at all time points exceeded 0.70,
which is a common minimum standard for internal
consistency reliability, and suggestive that the FKSI-
DRS can be used as an independent measure of
disease-related symptoms and functioning. The stabil-
ity of the FKSI-DRS over time was high, with an ICC
of 0.85 between time 1 and time 2 (range of possible
values = 0.0–1.0). Thus, the symptom index shows
high test–retest reliability between baseline and
3–7 days post baseline.
Convergent validity. The associations between FKSI-
DRS, FACT-G and subscale scores were evaluated
using Spearman correlations. Because it captures
physical symptoms of disease, the FKSI-DRS was
expected to be most highly correlated with the PWB
subscale of the FACT-G, and correlated to a slightly
lesser extent with the FWB domain compared with
psychosocial (EWB and SWB) scores. Indeed, this was
the case at both time 1 and time 3, with very high
correlations between FKSI-DRS and PWB scores (r
range = 0.84–0.85) and FWB scores (r range = 0.69–
0.71). As would be expected because of its content
of disease-related physical symptoms, correlations
between FKSI-DRS and EWB and SWB were low to
moderate (r range = 0.30–0.52). The FKSI-DRS con-
tains two PWB items. Therefore, these correlations
were inﬂated by redundancy. Nevertheless, even after
redundancy was removed and the FKSI-DRS was cor-
related with an abbreviated PWB score, removing all
overlap, correlations remained comparable. The FKSI-
DRS correlation with the ﬁve-item PWB at both time 1
and time 3 was 0.78. In all cases, including those
corrected for overlap, correlations between FKSI-DRS
and FACT-G scales were signiﬁcant at P < 0.0001 with
the exception of SWB at time 3, which was signiﬁcant
at P < 0.001.
Discriminant (known-groups) validity. The ECOG
PSR was trichotomized into PSR = 0, PSR = 1, and
PSR > 1. For the FKSI-DRS, all scores across PSR
groups were in the appropriate direction, that is,
patients with the lowest PSR (i.e., best performance
status) had the highest FKSI-DRS scores (i.e., greater
well-being and symptom status), and those with higher
PSR had FKSI-DRS scores reﬂecting poorer well-
being and symptom status (Table 3). Based on cross-
sectional analyses, the FKSI-DRS differentiated
patients grouped by PSR (P < 0.0001). Effect sizes
were calculated for group comparisons to provide an
indication of the clinical signiﬁcance of group differ-
ences. Following Cohen’s guidelines for effect sizes
[12], effect sizes for adjacent PSR groups were moder-
ate to large for the FKSI-DRS (e.g., 0.69–1.01).
Responsiveness to clinical change. Changes in FKSI-
DRS scores were calculated by subtracting patients’
time 1 scores from the time 3 scores. Patients’ GRCS
scores were categorized as “worse,” “same,” or
“better” by collapsing GRCS domain scores that were
rated on a 15-point scale (-7 through 0 to +7). As a
result of sample size restrictions at the extremes of
change, all gradations of change were collapsed into
one “changed” category for worse and one category
for better. GRCS scores were categorized as “worse” if
they were rated <-1, “same” if rated -1 to +1, and
“better” if rated >+1. ANOVA techniques were used to
compare mean change scores on the FKSI-DRS
between categories of change (better, same, worse) in
each anchor variable (GRCS domain). It is important
to note that the practice of pooling all globally
changed patients into one group will extend the mag-
nitude of change beyond “minimal,” because it
Table 3 Effect sizes of FKSI-DRS: cross-sectional (baseline) scores by ECOG performance status and longitudinal scores by GRCS
Scale ECOG PSR n Mean (SD) Common SD
Group comparisons
Group Mean difference Effect size* P-value
FKSI-DRS 0 65 32.70 (2.91) 5.40 0–1 5.48 1.01 <0.0001
1 50 27.22 (4.16) 0–2 9.22 1.71
2 25 23.48 (6.02) 1–2 3.74 0.69
FKSI-DRS change‡ Worse 13 -3.15 (3.18) 3.9 Worse vs. same -3.11 -0.80 0.0024†
Same 108 -0.04 (3.72) Same vs. better -2.34 -0.60
Better 10 2.30 (4.74) Worse vs. better -5.45 -1.40
*Calculated for adjacent categories.
†Difference is between GRCS Worse versus Same and Better; no difference between Same and Better. Worse: GRCS < -1; Same: GRCS -1 to +1; Better: GRCS > 1.
‡FKSI-DRS score change: score at time 3 minus score at time 1 (baseline).
ECOG PSR, Eastern Cooperative Oncology Group Performance Status Rating; FKSI-DRS, Functional Assessment of Cancer Therapy—Kidney Symptom Index: Disease-Related
Symptoms; GRCS, Global Rating of Change Scale.
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includes categories of change that exceed minimal by
the patient’s own judgment.
Changes in FKSI-DRS scores were in the anticipated
direction, such that patients who rated themselves as
worse on the GRCS had worsening scores on the FKSI-
DRS (Mean [SD] = -3.15 [3.18]), patients who rated
themselves as improved on the GRCS tended to have
improvements in the FKSI-DRS (2.30 [4.74]), and
patients who reported remaining the same on the
GRCS tended to have change scores for most subscales
scores that were in between the two other groups
(= -0.04 [3.72]) (see Table 3). In addition, changes in
FKSI-DRS scores were signiﬁcantly different between
the “worse” versus “same” and “better” groups
(F2,128 = 6.34, P = 0.0024).
Estimating important differences. Distribution- and
anchor-based methods were used to estimate FKSI
score changes that represent “clearly” important dif-
ferences (CIDs) and that might approximate MIDs.
Distribution-based estimates included 1/2 SD, 1/3 SD,
and 1 standard error of measurement (SEM). Anchors
used were the PSR and the GRCS. Because of the
course nature of the clinical anchors and the collapsing
of changes of any magnitude into one group, we con-
sidered them to provide conservative estimates of
CIDs rather than being MIDs. Table 4 displays the
distribution-based estimates of these differences at
baseline, time 3 and change from baseline to time 3.
The full range of distribution-based MIDs for the
FKSI-DRS was 1–3 points, with most estimates in the
2–3 point range.
Cross-sectional (PSR) anchor-based criteria yielded
larger estimates, again not necessarily reﬂecting MIDs.
As displayed in Table 3, effect sizes for baseline scores
of adjacent PSR groups ranged from 0.69 to 1.01
(approximately 4–5 points) for FKSI-DRS. The GRCS
was analyzed as a longitudinal clinical anchor to deter-
mine MIDs. The longitudinal anchor-based criteria
yielded estimates closer to the distribution-based esti-
mates, with effect sizes for adjacent GRCS groups
ranging from 0.60 to 0.80 for FKSI-DRS (approxi-
mately 2–3 points).
The effect sizes for the cross-sectional and longitu-
dinal anchor-based CID estimates using PSR for FKSI-
DRS are in the moderate to large range [12]. Change
scores associated with effect sizes >0.50 (moderate)
exceed what would be considered minimal. Reconcil-
ing the rather large effect sizes of the anchor-based
comparisons with the smaller distribution-based esti-
mates, it is reasonable to suggest 2–3 points as the
MID range for the FKSI-DRS.
Discussion
The objective of this study was to develop and validate
the FKSI-DRS, a brief scale to assess kidney cancer-
related symptoms. The FKSI-DRS was derived from
the FKSI-15, which is comprised of symptoms and
concerns rated by patients and clinicians to be the most
important to monitor when treating advanced kidney
cancer.
Fourteen of the 15 FKSI items rated by expert pro-
viders as primarily disease-related were accepted by
patients as such, and patients added fatigue to the
eight-item list they were shown based on the interim
(n = 18) results of the expert survey. Interestingly,
results from the completed (n = 31) expert survey also
included fatigue and, marginally, lack of energy.
Because this is an important area to kidney cancer
patients, and people differ on how they might distin-
guish fatigue from “lack of energy,” we have retained
both fatigue-related items in the FKSI-DRS. The other
symptom area that allocates two items in the FKSI-
DRS is pain, which also seems ﬁtting based on a survey
of National Comprehensive Cancer Network provid-
ers indicating these are the two most important symp-
toms in advanced solid tumors [13]. Appetite loss
might arguably have a place on the list; however,
experts failed to rate appetite as any more disease-
related than treatment-related in this disease. In
contrast, weight loss was seen as more clearly disease-
related. One of the surveyed patients also indicated
that having weight loss on the list covers appetite to a
signiﬁcant degree. Finally, we decided to remove the
“worry” item even though experts stated almost
unanimously that it is related to disease and not treat-
ment. Worry is clearly a very important concern to
people with cancer. Nevertheless, unlike all of the
other symptoms selected, it is unlikely that worry is
Table 4 Distribution-based estimates of minimally important differences (MIDs) for FKSI-DRS
n 1/3 SD 1/2 SD Criterion SEM Likely range of MID
FKSI-DRS
Baseline 141 1.80 2.70 2.11 2–3
Time 3 131 1.76 2.65 2.07
Baseline to time 3 change 131 1.30 1.95
SEM = sx (1 - rxx)1/2.
sx = the standard deviation of the scale/aggregate score.
rxx = the reliability (internal consistency) of the scale/aggregate score.
FKSI-DRS, Functional Assessment of Cancer Therapy—Kidney Symptom Index: Disease-Related Symptoms.
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caused by tumor invasion or metastasis in a direct
biological way. Rather it is an emotional reaction to
symptoms or concern over one’s condition or outlook.
New therapeutics are unlikely to be approved because
they make people worry less, and indeed it is usually
the case that people feel some relief from worry when
they embark on any new and hopeful treatment
course. We wish to minimize in this index the record-
ing of the emotional boost one gets from starting and
proceeding through a course of chemotherapy for
advanced disease. As we are unable to locate in the
literature a direct link between worry (a psychological
concept) and tumor invasion or metastases, we felt it
most appropriate to exclude the question.
The FKSI-DRS performed well psychometrically.
The internal consistency reliability coefﬁcients at all
time points exceeded acceptable standards. There was
evidence of convergent, divergent and known-groups
validity. The FKSI-DRS demonstrated responsiveness
to change in clinical status over time, and it success-
fully differentiated patients who reported improve-
ment, no change or worsening in their status across
multiple FACT-G domains. Cross-sectional and longi-
tudinal distribution-based criteria suggested estimates
of MIDs for the FKSI-DRS of 2–3 points. Cross-
sectional and longitudinal anchor-based criteria were
suggestive of larger clinically important differences,
reﬂecting large effects in excess of the likely MID. We
suggest 2–3 as the MID range for the FKSI-DRS. This
study was limited in the sense that the FKSI-DRS scale
analyzed was administered as a full FKSI-15 scale
rather than as a simpliﬁed FKSI-DRS. We therefore
assume that extraction of FKSI-DRS item responses
from the FKSI-15 administration accurately reﬂects
what people would answer had they only reported the
FKSI-DRS. Interested investigators can either adminis-
ter the full FKSI-15 or extract FKSI-DRS scores as we
did, or re-evaluate the FKSI-DRS in a second valida-
tion effort with only these nine questions.
In conclusion, the nine-item FKSI-DRS appears to be
a reasonably concise list of symptoms caused by kidney
cancer. The FKSI-DRS is an index to gauge treatment
impact on the most important symptoms, from the
perspective of both patients and clinical experts.
Source of ﬁnancial support: Supported in part by unrestricted
grants from Pﬁzer and Bayer Pharmaceuticals.
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Appendix I
FKSI—Disease-Related Symptoms (FKSI-DRS)
Below is a list of statements that other people with your illness have said are important. By circling one (1) number
per line, please indicate how true each statement has been for you during the past 7 days.
Not at all A little bit Somewhat Quite a bit Very much
I have a lack of energy 0 1 2 3 4
I have pain 0 1 2 3 4
I am losing weight 0 1 2 3 4
I have bone pain 0 1 2 3 4
I feel fatigued 0 1 2 3 4
I have been short of breath 0 1 2 3 4
I have been coughing 0 1 2 3 4
I am bothered by fevers 0 1 2 3 4
I have had blood in my urine 0 1 2 3 4
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